A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer

Inclusion Criteria: * Histological or cytological evidence of adenocarcinoma of the prostate and have metastatic disease. * Patients must have received only one prior regimen for their advanced disease. This regimen must have included a taxane. * First Stratum Eligibility: Patients must have advanced, metastatic prostate cancer with documented progression after receiving more than three months of treatment, up to a total of 10 months with 1 prior taxane regimen. Prior best response to treatment, and duration of response, will be recorded. * Second Stratum Eligibility: Patients must have advanced, metastatic prostate cancer that has progressed as best response despite three months or less of treatment with 1 prior taxane regimen. * Must have castrate levels of testosterone less than 50 ng/mL * Must have an ECOG Performance Score of 0 or 1 * Must be age 18 or older * Must be able to read, understand and sign informed consent * Serum creatinine less than or equal to 2.0 mg/dL * Total bilirubin less than or equal to 2.0 mg/dL * SGOT/SGPT less than or equal to 3 times the ULN * ANC greater than or equal to 1500/UL * Platelet count greater than or equal to 100,000/UL Recovered from the effects of prior surgery, radiotherapy or other antineoplastic therapy. Exclusion Criteria: * Active infection or with a fever greater than or equal to 38.5 degrees centigrade within 3 days of first scheduled day of dosing * More than one prior systemic therapy for HRPC beyond androgen-ablative therapy. Prior systemic therapy may have been administered for metastatic disease or as adjuvant therapy * Has received radiotherapy to greater than 30% of their active bone marrow * History of prior malignancy within the past 5 years except for curatively treated non-melanoma skin cancer * Impending fracture of a weight bearing bone * Known hypersensitivity to any of the components of TPI 287 * Receiving concurrent investigational therapy or who have received investigational therapy within 30 days of study start * Grade 2 peripheral neuropathy * NYHA Class 3 or 4 congestive heart failure * Any medial condition that would interfere with ability to sign ICF, cooperate and participate in the study or interfere with interpretation of results * History of allogenic transplant * Know HIV or Hepatitis B or C positive